We started Galdera Labs Capital because the best science in life sciences keeps coming out of academic labs — and most of it never makes it to patients. We wanted to close that gap from the capital side.
Galdera Labs Capital was founded in 2019 in La Jolla, California — a deliberate choice. The density of serious life sciences research within five miles of our office is hard to replicate anywhere else. Scripps Research, UCSD, Salk, and the Sanford Consortium sit within walking distance of each other, and of us. That proximity is not decorative. It shapes how we source, how we diligence, and who we hire.
Our founding mandate was narrow on purpose: back companies at the intersection of hard science and genuine translational potential. We are not generalists who allocate to healthcare. We focus on drug discovery platforms, genomics infrastructure, and diagnostics — areas where scientific credibility matters more than storytelling, and where the timeline to value creation is measured in years, not quarters.
We are venture-backed ourselves, which keeps us accountable to performance. But we have structured our fund to support long-cycle biotech: our primary fund has an eight-year life with two optional extensions, and we are not shy about using them. We have seen too many good science companies rushed into premature liquidity because their investors ran out of patience. That is not our approach.
We do not spread bets across all of healthcare. Three areas get our sustained attention — because they are large enough to matter and scientifically ripe enough to produce real outcomes in our fund cycle.
We back platform-stage companies building better ways to find, validate, and advance drug targets. Seed through Series A entry; typical check $3–8M led. Small molecules and biologic modalities. We want infrastructure that speeds up discovery, not individual programs.
We invest in sequencing technology, data infrastructure, interpretation software, and single-cell tools where defensibility is durable — read-out tech and analytical platforms with network effects. The genomics stack is still being built and we want the foundational layers.
We back founders in liquid biopsy, companion diagnostics, spatial pathology, and evidence-backed digital therapeutics who have thought seriously about reimbursement from day one. Clinical utility data is a requirement, not a follow-up.
The investment decision starts with the biology. Market size matters, but not more than whether the science actually holds up. We invest after we understand the mechanism.
Biotech is a long game. We structure our funds to match that reality. We do not mark-to-model and declare victory. We wait for real clinical and commercial inflections.
Our advisors and portfolio alumni include regulatory strategists, KOLs, and commercial leaders who have actually launched in life sciences. We connect founders to the people who matter.